Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

44.67USD
29 Mar 2017
Change (% chg)

-- (--)
Prev Close
$44.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,573,053
52-wk High
$45.84
52-wk Low
$36.76

ABT

Chart for ABT

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $77,189.66
Shares Outstanding(Mil.): 1,728.00
Dividend: 0.26
Yield (%): 2.37

Financials

  ABT Industry Sector
P/E (TTM): 62.38 29.56 30.32
EPS (TTM): 0.72 -- --
ROI: 2.73 13.57 13.10
ROE: 5.09 14.48 14.24

Higher heart risk seen with Abbott dissolving stent after two years: study

WASHINGTON Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.

Mar 18 2017

UPDATE 1-Higher heart risk seen with Abbott dissolving stent after 2 years -study

WASHINGTON, March 18 Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.

Mar 18 2017

Higher heart risk seen with Abbott dissolving stent after 2 years -study

WASHINGTON, March 18 Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.

Mar 18 2017

BRIEF-Abbott Laboratories says CEO Miles White total compensation for 2016 $20.3 mln vs. $19.4 mln in 2015

* Abbott laboratories says chairman and ceo miles white total compensation for 2016 $20.3 million versus. $19.4 million in 2015 Source text for Eikon: Further company coverage:

Mar 17 2017

BRIEF-Abbott says findings from Lotus I study may have important implications for women undergoing IVF

* Abbott Laboratories - findings from Lotus I study have potential to have important implications for women undergoing IVF

Mar 08 2017

Diagnostic company Alere to delay filing annual report

Alere Inc said it would delay filing its 2016 annual report, in the latest blow to the diagnostic company engaged in a legal battle with Abbott Laboratories over their deal.

Mar 01 2017

UPDATE 2-Diagnostic company Alere to delay filing annual report

March 1 Alere Inc said it would delay filing its 2016 annual report, in the latest blow to the diagnostic company engaged in a legal battle with Abbott Laboratories over their deal.

Mar 01 2017

BRIEF-FTC approves final order settling charges for Abbott's deal with St. Jude Medical

* Approved final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would likely be anticompetitive

Feb 23 2017

BRIEF-Abbott Laboratories commences exchange offers, consent solicitations for St. Jude Medical notes

* Abbott laboratories - Abbott commences exchange offers and consent solicitations for St. Jude Medical LLC notes Source text for Eikon: Further company coverage:

Feb 21 2017

BRIEF-Abbott Laboratories says board of directors shall consist of 12 persons from 11

* Abbott Laboratories-on Feb 16, amended by-laws to provide that co's board of directors shall consist of 12 persons, effective as of February 16, 2017

Feb 17 2017

More From Around the Web

Competitors

Earnings vs. Estimates